Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Drugs. 2020 Feb;80(3):217–227. doi: 10.1007/s40265-019-01249-z

Table 1:

Summary of anti-angiogenic therapeutic agents studied in the treatment of cervical cancer.

Drug Additional Therapy Mechanism of Action Trial Potential Toxicities
Bevacizumab cisplatin/paclitaxel
or
topotecan/paclitaxel		 Anti-VEGF-A GOG 2406 Hypertension, thrombosis, nephrotic syndrome, rash, bowel perforation, headache
carboplatin/paclitaxel CECILIA28
Pazopanib [monotherapy] Anti-VEGFR-1,2,3 Monk et al31
Lapatinib [monotherapy] Anti-EGFR
Anti-Her2/neu
Neratinib [monotherapy] Anti-Her2/neu SUMMIT32
Cediranib carboplatin/paclitaxel Anti-VEGFR-1,2,3 CIRCCa33
Cetuximab cisplatin Anti-EGFR GOG-0076D34
Sunitinib [monotherapy] Anti-VEGFR-1,2,3 NCIC CTG Trial IND.18435
Nimotuzumab cisplatin/vinorelbine Anti-EGFR 36
concurrent chemoradiation 37
Nintedanib carboplatin/paclitaxel Anti-VEGFR, FGFR, PDGFR 38
Apatinib paclitaxel + cisplatin or carboplatin Anti-VEGFR 2 39

CIRCCa = Cediranib combined with carboplatin and paclitaxel in patients with metastatic or Recurrent Cervical Cancer; EGFR - Epidermal Growth Factor Receptor; GOG = Gynecologic Oncology Group; Her2 = Human Epidermal Growth Factor; NCIC CTG = National Cancer Institute of Canada Clinical Trials Group; NCT = National Clinical Trials; VEGF = Vascular Endothelial Growth Factor (R = Receptor);